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Simple Summary: Recent advances in nanotechnology gave rise to trials with various types of
metallic nanoparticles (NPs) to enhance the radiosensitization of cancer cells while reducing or
maintaining the normal tissue complication probability during radiation therapy. This work reviews
the physical and chemical mechanisms leading to the enhancement of ionizing radiation’s detrimental
effects on cells and tissues, as well as the plethora of experimental procedures to study these effects
of the so-called “NPs’ radiosensitization”. The paper presents the need to a better understanding of
all the phases of actions before applying metallic-based NPs in clinical practice to improve the effect
of IR therapy. More physical and biological experiments especially in vivo must be performed and
simulation Monte Carlo or mathematical codes based on more accurate models for all phases must
be developed.
Abstract: Many different tumor-targeted strategies are under development worldwide to limit the
side effects and improve the effectiveness of cancer therapies. One promising method is to enhance
the radiosensitization of the cancer cells while reducing or maintaining the normal tissue complication
probability during radiation therapy using metallic nanoparticles (NPs). Radiotherapy with MV
photons is more commonly available and applied in cancer clinics than high LET particle radiotherapy,
so the addition of high-Z NPs has the potential to further increase the efficacy of photon radiotherapy
in terms of NP radiosensitization. Generally, when using X-rays, mainly the inner electron shells are
ionized, which creates cascades of both low and high energy Auger electrons. When using high LET
particles, mainly the outer shells are ionized, which give electrons with lower energies than when
using X-rays. The amount of the produced low energy electrons is higher when exposing NPs to
heavy charged particles than when exposing them to X-rays. Since ions traverse the material along
tracks, and therefore give rise to a much more inhomogeneous dose distributions than X-rays, there
might be a need to introduce a higher number of NPs when using ions compared to when using
X-rays to create enough primary and secondary electrons to get the desired dose escalations. This
raises the questions of toxicity. This paper provides a review of the fundamental processes controlling
the outcome of metallic NP-boosted photon beam and ion beam radiation therapy and presents some
experimental procedures to study the biological effects of NPs’ radiosensitization. The overview
shows the need for more systematic studies of the behavior of NPs when exposed to different kinds
of ionizing radiation before applying metallic-based NPs in clinical practice to improve the effect of
IR therapy.
Keywords: metallic nanoparticles (NPs); radiosensitization; radiation therapy; X-rays; ions beam therapy
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1. Introduction
Many different tumor-targeted strategies are under development worldwide to limit
the side effects and improve the effectiveness of cancer therapies, such as the currently
developed very high dose rate FLASH therapy, chemotherapy, immunotherapy, intensity
modulated radiation therapy, biology-driven personalized radiotherapy, ion beam radio-
therapy, target-alpha-therapy, high intensity focused ultrasound therapy, hyperthermia,
biophotonic therapy, etc. During the last 10–15 years, advances in nanotechnology also
gave rise to trials with various types of metallic nanoparticles (NPs) to sensitize cancer cells
to radiotherapy (RT), and was used in different medical applications ranging from contrast
agents in site-specific imaging to carriers for drug, heat, and gene delivery into tumors. The
radiosensitizing effect by an iodine contrast agent was first reported by Matsudaira et al. in
1980 [1], and the radiosensitization effect by high-Z metallic was first observed in patients
with metallic implants who received radiotherapy for the treatment of mandibular [2]
and head and neck cancers [3]. At that time, the radiation modification effects associated
with metallic implants caused troubles for the medical radiation physicists, leading to the
conceptualization of an appropriate dosimetry protocol by the American Association of
Physicists in Medicine (AAPM) to overcome the arising problems [4]. Image reconstruction
errors due to radiosensitization from metallic implants are also known affects in all the
radiation therapy planning processes and is discussed in [5]. Metal complexes based
of platinum demonstrated an essential impact in cancer chemotherapy. However, other
high-Z metal such as titanium, ruthenium, copper and silver shown promising cytotoxic
and chemotherapeutic characteristics in recent preclinical research, while iron, cobalt, and
gold were already used in phase I and phase II trials [6].
Many studies [7,8] review the efficacy of metallic-based nano-agents expressing ra-
diosensitizing and synergistic effects for radiotherapy (including gamma-rays, X-rays, and
charged particles), and they termed these NPs as “NanoEnhancers”. They briefly present
several categories of metallic-based NanoEnhancers for ionizing radiation (IR), as: gold
(Z = 79), platinum (Z = 78), hafnium (Z = 72), gadolinium (Z = 64), and iron (Z = 26) based
NPs, as well as theragnostic multimetallic nanocomposites for future RT. The enhanced
synergistic effects and therapeutic outcome of high-Z metallic NPs mediated radiosen-
sitization were tested in multiple preclinical tumor models, including glioblastoma [9].
Moreover, based on the success of preclinical studies, several clinical trials are underway
to show the efficacy of the high-Z metallic NP mediated radiosensitization [9].
The radiosensitization by high-Z metallic NPs is caused by a physical dose enhance-
ment followed by radiochemical and biological reactions in the tissue. The physical dose
enhancement is caused by generation of secondary X-rays, photoelectrons, and Auger elec-
trons. The chemical/biological steps include oxidative stress and reactive oxygen species
(ROS) production, DNA damage and reduce repair, cell cycle arrest, and bystander effects.
When using X-rays, mainly the inner electron shells are ionized, which creates cascades
of both low and high energy Auger electrons. Depending on the energy of the incoming
photons, protons or carbon ions, and the atomic number of the irradiated metallic NPs,
Compton electrons, scattered electrons, positrons, and fluorescent emission can occur, as is
schematically shown in Figure 1. During proton and carbon ion irradiation, fragmentation
reactions can also occur.
For photon irradiation, the photoelectric cross-section effect depends roughly on
(Z/E)n, with n≈3–4, where E is the energy of the incoming photon and Z is the atomic num-
ber of the target atom. The photoelectric effect is therefore dominant at lower energies and
is prevailing until the photon energy reaches a medium energy (typically up to≈500 keV)
with high Z atoms (Z ≈ 60–80). Therefore, the most explored high Z radio-sensitizing
agents are typically comprised of gold (Z = 79), platinum (Z = 78), hafnium (Z = 72), or
gadolinium (Z = 64) [10], but even e.g., silver (Z = 47) and iron (Z = 26) were studied.
Increasing the Z of the NPs is enhancing the photoelectric and Compton effects when they
are exposed to X-rays. High-Z NPs are therefore more radio-sensitizing when using X-rays
than low Z NPs. Gold is a promising radio-sensitizer due to its high atomic number and
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mass energy coefficient relative to soft tissue. In addition to that, it is very inert and highly
biocompatible.
Figure 1. Interaction of X-rays, protons, and carbon ions with high-Z metals.
In conventional radiation therapy, X-rays consist of a mixture of x-ray waves with
various energy levels. By using a monochromator, the white X-rays which are normally
used in medical applications can be separated into monochromatic X-rays, with each
having a single energy level. Irradiation of high Z NPs with a synchrotron producing
monochromatic X-rays with an energy level that is same or higher than the K-edge energy
of the metallic material used in the NP is very promising [11]. These local ejections of
K-shell electrons result in the production of Auger electrons that cause DNA damage which
can lead to cell killing. Most of these studies were performed at synchrotron radiation
sources in ESRF France. For example, Dalzon et al. found an improved radiotherapeutic
effect of synchrotron radiation when combined with iron oxide NPs [12]. Matsumoto
et al. irradiated tumor spheroids with a synchrotron producing monochromatic X-rays in
combination with gadolinium-loaded MCNs (mesoporous silica nanoparticles) [13]. This
resulted in a complete tumor destruction at an energy level of 50.25 KeV. The same effect,
however, was not observed at an energy level of 50.0 KeV, which suggests that a precisely
tuned monochromatic x-ray can target a tumor while sparing neighboring cells. Bulin et al.
presented LaF3:Ce nanoscintillators (doped lanthanum fluoride nanoparticles) as potent
radiosensitizers [14]. They performed a comprehensive study with Geant4-based Monte
Carlo simulations, as well as in vitro and in vivo experiments. In a syngeneic orthotopic
glioblastoma in vivo model they monitored toxicity and radiotherapy enhancement in
combination with monochromatic X-rays, which showed a 15% tumor remission. Finally,
Gagliardi et al. used synchrotron radiation is PRESAGE dosimeters in the presence of
gold and bismuth NPs to validate the dose enhancement effect. By using these NPs in
different concentrations and sizes, the observed dose enhancement was highest for the
95.3 keV mean energy synchrotron beam (16–32%), followed by the 150 kVp superficial
beam (12–21%), and then the 6 MV beam (2–5%) [15].
When using high LET particles, e.g., carbon ions for therapy, mainly the outer shells
are ionized, which give rise to electrons with lower energies than when using X-rays.
However, the amount of the produced low energy electrons is higher when exposing NPs
to ions than when exposing them to X-rays. Since ions traverse the material along tracks,
and therefore give rise to much more inhomogeneous dose distributions than X-rays, there
might be a need to introduce a higher number of NPs when using ions compared to when
using MV energies to create enough primary and secondary electrons to get the desired
dose escalations. However, the use of metallic NPs in radiotherapy at clinical MV energies
has the potential to increase the dose deposited in target volumes even at relatively low
concentrations [16,17]. For example, dose enhancement ratios ranging from 14–287% were
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observed with within 6 MV Linac beams using gold nanoshells with shell thickness varying
from 10–100 nm [18].
Simulation studies support that the radiation sensitization enhancement factor is
higher for kV photons than photons in the MV range [19,20]. This was also experimen-
tally verified by Chithrani et al. [21], who exposed HeLa cells with 50 nm gold NPs to
photons with energies from 105 KVp to 6 MVp. Recent Monte Carlo simulations of the
radio-enhancement effects of different concentrations, sizes, clustering of gold NP (AuNP)
bombarded with photons, protons, and carbon ions with a wide range of energies show
that in all radiation modalities, the dose enhancement increased linearly with the AuNP
concentration and decrease with AuNP size and degree of clustering [22]. However, the
NPs size and concentration are correlated with cellular uptake and toxicity, as it is dis-
cussed further down. The dose enhancement effect in cytoplasm and nucleus is higher
for 50 keV X-rays than for 10 MeV protons and 100 MeV carbon-ions. This is directly
correlated with the previously mentioned produced electron energies for each type of
IR. Geant4 simulations also show that the electron spectra from X-rays at the surfaces of
AuNPs show a strong distribution of Auger electrons around 2 keV, while the number
of the emitted low energy electrons is about 28 times larger for 10 MeV carbon-ions in
comparison with 1 MeV protons correlating with the 27 times higher LET [22]. However, in
the case of proton interactions the production of radicals upon energy deposition (G-value)
is sensitive to the size of the NPs with more radical interactions for AuNP with 2 nm than
for particles with 50 nm diameter for the same concentrations. The dose enhancement
linearly decreased with AuNP size and degree of clustering [22]. Similar ROS enhancement
factors were observed when irradiating gadolinium oxide (Gd2O3) NPs with X-rays and
protons with the same dose [23]. In general, ion irradiation damage is thought to be due
to either nuclear or electronic energy loss [24]. In electronic stopping power, damage is
believed to be produced only above a threshold, whereas nuclear damage is still significant
in the energy regime just above the energy ion track threshold [25]. For ionizing particles,
the damage produced by nuclear stopping power is more considerable with respect to
electronic stopping power.
Nanoparticles enter the body by crossing outer layers either in skin or tissue organs,
they can otherwise be inhaled, infused, or injected into the body or into the bloodstream.
NPs used for radiosensitization can be either therapeutic agents (e.g., cisplatin, drug
conjugated/encapsulated NPs) or inert therapeutic NPs (e.g., AuNPs) [26–29]. The first can
sensitize cells alone, the second or a combination of both can act as radiosensitizers when
combined with IR exposure [30,31]. NPs can be administered either locally by surgical or
nonsurgical procedures along with NP/drug-loaded implants or systemically by injection,
inhalation etc., depending on the selected route and the tumor site. Desired is a systemic
administration of NPs (with or without anticancer drugs) to target cancerous cells at
the desired tumor site with marginal loss in blood circulation. The two main targeted
delivery pathways are passive targeting and active targeting [32,33]. Passive targeting
uses the enhanced permeability and retention (EPR) effect, allowing macromolecules of
diameter up to 400 nm to pass into the tumor cells (drug/NP complex circulates through
the bloodstream and is driven to the target site by affinity or binding which are influenced
by properties like pH, temperature, molecular site, and shape), whereas active targeting
uses surface ligands (peptides, antibodies etc.) to enhance accumulation and cellular
uptake of NPs via receptor-facilitated endocytosis [33]. Research shows that smaller NPs
(~10 nm) reach most organs, while larger NPs (>100 nm) are mainly held in the spleen
and liver. For example, an in vivo study in mice reported that intravenous injection of
fluorescent PLGA-NPs of sizes 200 nm and 500 nm were accumulated highest in the liver,
spleen, and lungs [34]. Inhalation of NPs is usually used for treatment of lung cancers,
as it is more successful in terms of accumulation and retention since the escape of NPs
into circulation is limited [35,36]. Some of the NPs used for delivery via inhalation include
GNPs, cisplatin NPs, carboplatin NPs [36]. Monte Carlo simulations showed an increased
DEF (decreasing tumor volume) when applying NPs through inhalation in combination
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with chemo-radiotherapy with 6 MV external beam RT [36]. On the other hand, local
delivery results in high concentration of NPS in the desired area, which decreases body
toxicity. This method can be very advantageous especially in tumor sites, where systemic
delivery fails. This delivery system includes direct intratumoral injection, or the use of
biodegradable polymeric implants such as gels, wafers, millirods etc. [37,38]. However, the
discussion regarding delivery of NPs is directly correlated with their material, size, shape,
surface functionalization etc.
The physicochemical properties (size, shape, coating, functionalization, etc.) of nano-
agents influence their pharmacokinetics, bioavailability, biodistribution, as well as targeting
and intracellular delivery. The physical and chemical properties of materials are different
in the nanometer scale than in macroscale [39] and the size of the NPs used for radiosensi-
tization affects both how they interact with the biological system and how they interact
with the incoming radiation. The sizes of the NPs are a critical parameter since small NPs
with sizes ~10 nm are able for nuclear uptake but they are easily cleared from circulation
through kidneys. On the other hand, too large NPs ~100 nm can limit the membrane
wrapping efficiency [40]. Moreover, the concentration of the NPs in combination with the
size can affect the NPs efficiency and toxicity. High concentrations of some metallic NPs
can increase the probability for aggregations and the toxicity, while NPs can be not toxic at
low concentrations [41,42].
The surface functionalization of NPs is strongly correlated with the cellular uptake
and the subcellular location. The functionalization can be achieved by coating NPs surface
with polyethylene glycol (PEG) or by attaching on their surface antibodies, phospholipids,
polymers and other biomolecular linkers depending on chemical moiety that is over
expressed in each type of cancer cell [43,44]. The NPs should overcome several extra- and
intracellular barriers to reach their target cells. Thus, the surface functionalization should be
the proper one to circulate in blood plasma avoiding the activation of the reticuloendothelial
system (RES) and to be able to escape from endosome after their internalization in the cells.
On a cellular level, NPs can be internalized in the nucleus, cell organelles, such as
mitochondria and endoplasmic reticulum or located in the cell membrane. The subcellular
location affects the radiosensitization efficacy [45–47]. The highest dose enhancement
seems to be achieved when metallic NPs are located close to the nucleus where the energy
deposition from Auger electrons is highest [48]. However, simulations show that when
metallic NPs tend to localize in the cytoplasm like in mitochondria can also be effective
radiosensitizers [46,49]. Hossain et al. comparing different materials of nanoparticles for
a given size, concentration and location found that bismuth NPs demonstrated 1.25- and
1.29-times higher dose enhancements than Au and platinum NPs.
Figure 2 summarizes the key parameters for designing an effective NP-based radiosen-
sitization, in terms of NP size, shape, functionalization, cellular uptake, body circulation
and impending toxicity.
1.1. Most Promising Metallic NPs Proposed for RT
1.1.1. Gold (Au, Z = 79)
Au is a high Z, very inert transition metallic. Owing to their unique physical, chemical,
optical and electronic properties, AuNPs were exploited for a wide range of applications
in diagnostics, imaging, delivery, photothermal (use of electromagnetic radiation) and
ionizing RT. Multidisciplinary research performed over the past decade demonstrated the
potential of AuNP-based radiosensitizers and identified possible mechanisms underlying
the observed radiation enhancement effects of AuNPs [50]. The AuNP size, shape, surface
coating, and functionalization can be fine tailored, which enables fine-tuning of the particle
properties that is an important criterion to be used in different medical applications. AuNPs
can be fabricated in different shapes/morphologies such as spheres, tubes, cubes, cages,
stars hollow shells, hollow spheres, and hollow tubes. Au nanorods might have greater
cellular uptake compared to spherical NPs as they can have larger contact area with the
cell membrane receptors if they interact with their longitudinal axis. However, surface
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coating plays a key role for the cellular uptake to create efficient bonds with the receptors
on the cell’s surface [51]. Recently, Li and Lane [52] summarized the aspects of size, shape
and surface chemistry for fundamental understanding of how certain physicochemical
parameters affect the AuNPs ability to overcome biological obstacles in vivo and reach
their intended target. They focused on how AuNPs face biological obstacles that are seen by
intravenously administered nanomedicines including opsonization, cellular internalization,
tumor accumulation, and elimination from the body. Recently, the correlation between
the sizes of the AuNPs and uptake, toxicity, radiosensitization, and radiation survival was
reviewed [53,54]. This study summarizes several in vitro and in vivo experimental results
on uptake and radiation therapy enhancement. Non-targeted AuNP with sizes around
50 nm seem to have maximum cellular uptake.
Figure 2. Key parameters for designing an effective NP-based radiosensitizing effect in RT, and
known main mechanisms associated with use of metallic NPs in RT.
1.1.2. Platinum (Pt, Z = 78)
Pt is a high-Z member of the platinum group of elements of the periodic table of
elements. Pt has significant radiosensitizing properties and Pt anticancer agents represent
a great success story which were introduced to the market almost 40 years ago. Three
Pt-containing drugs are approved worldwide for treating cancer in humans, cisplatin
carboplatin, and oxaliplatin. In addition, nedaplatin, lobaplatin, and heptaplatin are ap-
proved for use in specific countries. PtNPs were widely studied in biomedical applications
such as drug delivery bodies [55], contrasts agents in computed tomography imaging [56],
scavenger of reactive oxygen species [57], and radiosensitizers [58]. Recently, Li et al.
show that ultra-small platinum NPs (1.7 nm) PtNPs with minimal inhibition concentration
of 4.8 mg/L can penetrate the 150 nm membrane thickness of D. radiodurans cells and
overcome its radioresistance [59] and the PtNPs enhanced the effects of 1.25 MeV gamma
ray radiation by more than 40%. PtNPs were shown to possess the capability to enter the
cells, generate oxygen, and cause single strand breaks (SSB) and double strand breaks (DSB)
in DNA though their interaction with X-rays, gamma rays, or ions. The size of the platinum
NPs seems to strongly affect their toxicokinetic. However, there are only few studies on
the size dependent toxic effects. Buchtelova et al. tested the cytotoxicity of three different
primary sizes of PtNPs (~10 nm, ~14 nm and ~20 nm) capped with biocompatible polymer
polyvinylpyrrolidone (PVP) on prostate, breast, and neuroblastoma cancer cell lines [60].
The results showed that the smaller PtNPs exhibited the highest cytotoxicity, while the
haemotoxicity seems not to be affected by the size. Porous PtNPs were proposed as a new
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nanomedicine platform to overcome radioresistance and to enhance radiotherapy in vivo.
The combination of the high Z and the oxygen generation capability can significantly
increase the X-ray radiation energy deposition within the cells, increase radiation-induce
DNA damage, ROS stress and increase tumor oxygenation by converting endogenic H2O2
to O2 with no apparent toxicity in animals [61]. Pt nanodedrimers (PtNDs) exhibit high
biocompatibility and radiosensitization toward Hela cell line up to 0.1 mM concentration
in all the tested sizes of 29, 36, 42, and 52 nm diameters. Among them, the PtNDs with 36
nm in diameter demonstrated the highest sensitization Enhancement Ratio (SER) after irra-
diation with 6 MV photon beam. The results demonstrate PtNDs as a novel and promising
radiosensitizer in radiotherapy but of possible high toxicity [62].
1.1.3. Hafnium (Hf, Z = 72)
Hf is a chemically stable inert transition metallic with high atomic number and
electron density. Hf dioxide/hafnia (HfO2) is also chemically inert and has a high dielectric
constant, high melting point, high density, high refraction index, and is transparent to
visible light. In addition to the mentioned properties, HfO2 does not have any adverse
reactions in biological systems and HfO2 NPs have therefore promising potentials to act
as radiosensitizing and X-ray contrast agents [63,64]. HfO2 has also photo-luminescent
properties [63] which indicates that HfO2 NP is a multifunctional theragnostic candidate.
NBTXR3 is a functionalized 50-nm-sized crystalline HfO2 NP, bearing a negative surface
charge, developed by Nanobiotix [65]. NBTXR3 was originally designed for direct local
intratumoral injections and subsequent radiosensitization. Preclinical studies showed that
NBTXR3 has a physical mode of action that does not target specific biological pathways, and
might provide an opportunity to improve patient outcomes in many types of cancer [66,67].
The results of the Act.In.Sarc study [66] suggest that NBTXR3 activated by radiotherapy
could represent a new treatment option in patients with e.g., locally advanced soft-tissue
sarcoma of the extremities or trunk wall. Moreover, these data open a large field of
applications and justify ongoing studies evaluating NBTXR3, including phase 1–2 trials in
head and neck squamous cell carcinoma, liver cancer, prostate cancer, rectal cancer, and
recurrent or metastatic head and neck squamous cell carcinoma or metastatic non-small-
cell lung cancer [66]. Since NBTXR3 improves the efficacy of radiotherapy, all patients
with resectable tumors eligible for preoperative radiotherapy treatment could benefit
from its use [66].
1.1.4. Gadolinium (Gd, Z = 64)
Gd is the most widely used paramagnetic element for MRI-positive contrast agents,
favored for its seven unpaired electrons and relatively long electronic relaxation times. Gd
chelates is commonly used as an MRI-contrast agent and for more precise and accurate
irradiation in MRI-guided radiotherapy. Several large studies demonstrated that Motexafin
Gd (MGd), which is a metallotexaphyrin that can catalyse the oxidation of intracellular
reducing metabolites and generate ROS, is capable of enhancing the cytotoxic effects of
radiation through several mechanisms as well as selectively inhibiting tumor cell growth
by itself [68]. Consequently, Gd-based agents show great promise for multifunctional
theragnostic (diagnostic and therapeutic) applications in clinical practice [63].
1.1.5. Silver (Ag, Z = 47)
Although Ag is a transition metallic with a lower atomic number than Au, it has
promising properties as a radiosensitizer. AgNPs are less inert and biocompatible than
AuNPs [29,69], but AgNPs are attractive in biomedicine due to that they are cheaper
and they have unique physicochemical properties. In recent years, the anticancer effect
of AgNPs was widely studied both in vitro and in vivo, for e.g., cervical cancer, breast
cancer, lung cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, hepatocellular
carcinoma, glioblastoma, colorectal adenocarcinoma, and prostate carcinoma [70]. Different
surface functionalization, shapes and sizes of AgNPs were studied for their effectiveness
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in cancer treatment combined with IR [29]. In [70] different AgNPs synthesis methods,
including physical, chemical and biological procedures, as well as medical applications and
biosafety are reviewed. AgNPs were used for antimicrobial and cancer therapy, as well as
for promotion of wound repair, bone healing, and as vaccine adjuvant, anti-diabetic agent
and biosensors. In RT, the anti-proliferative effects of AgNPs might result from different
underlying mechanisms compared to when using AuNPs [63,70]. It was suggested that
induction of apoptosis, production of ROS, inhibitory action on the efflux activity of drug-
resistant cells, and reactivity with glutathione (GSH) molecules are involved in the radiation
enhancement effect.
1.1.6. Iron (Fe, Z = 26)
Fe belongs to the first transition series of the periodic table and is by mass the most
common element on Earth. Fe-based NPs were investigated as theranostic magnetic
NPs [71,72], including inorganic paramagnetic iron oxide (or magnetite) NPs, or super-
paramagnetic iron oxide NPs (SPIONs) [73]. Fe oxide NPs (IONs) were used as negative
T2 MRI contrast agents and they are considered ideal agents for diagnosis, treatment, and
treatment monitoring of cancers because of their excellent properties, such as facile synthe-
sis, biocompatibility, and biodegradability [63]. IONs have therefore potential applications
not only as MRI contrast agents but also in photothermal therapy (PTT), photodynamic
therapy (PDT), magnetic hyperthermia, and chemo/biotherapeutics [63].
2. Effects of Size, Shapes, and Surface Treatments
It is difficult to determine the optimum size and shape for the best radiation enhance-
ment of NPs, since the NPs interacts both with the cell surfaces and with the different
receptors, which lead to different pathways. Small NPs with sizes 1–5 nm are good for
nuclear uptake, which is very important for NP-mediated radiation enhancement. Huo
et al. [74] showed that in MCF-7 breast cancer cells, NPs with diameters smaller than 10 nm
(2 nm and 6 nm) could enter the nucleus, whereas ones with diameter larger than 10 nm
were only located in the cytoplasm. However, too small NPs cannot enhance the radia-
tion because of their inability to occupy multiple receptor-mediated endocytosis binding
sites and their low binding avidity. On the other hand, too large NPs seem too large for
membrane wrapping [75], so sizes near 50 nm seem to be the optimal size for effective
uptake [75–77].
Spherical NPs, especially the ones coated with polyethylene glycol (PEG), have higher
uptake rates than other shapes [51,78,79], but other groups claim that rod-shaped NPs
are better endocytosed compared to spherical ones [79,80]. In case of spherical NPs,
the membrane wrapping time is smaller compared to the larger rod-shaped NPs. Herd
et al. [81] investigated the uptake of three silica NPs, spherical, cylindrical and worm-like
and their experiments suggest that microcytosis (clathrin-mediated endocytosis) is the most
favorable mechanism for spherical NPs, whereas their worm-like counterparts underwent
macropinocytosis or phagocytosis. For more details on shape and cellular uptake, see
also [82]. The cellular uptake of NPs is also dependent on the surface charge since the
electrostatic interactions between NPs and the cell membranes are of great importance.
Cationic NPs show greater cellular uptake because a positive charge has a much more
disrupted effect on the lipid bilayer [83]. Cho et al. showed that half of the cationic AuNPs
diffused into cells by generating holes or disrupted the cell membranes. Some of these
may refer to nonendocytosis pathways [84]. The surfaces of NPs can also be functionalized
with biomolecular chains, such as peptides, PEG moieties, or Bovine serum albumin (BSA),
which enhances the targeted effect of NPs especially for the nucleus [85–87]. NPs can also
form aggregates due to exposure to a high concentration of ions when they come into
contact with biological media [51]. Aggregation of NPs can quantitatively affect cellular
uptake and/or cellular distribution based on the NPs’ physiochemical properties and the
cell type. The most common coating for NPs, especially for AuNPs, is the citrate coating.
However, the physiological pH citrate-coated AuNPs have a high zeta potential which
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makes particles easily to aggregate [88]. PEG coated NPs with sizes 5–60 nm on the other
hand (especially AuNPs), increases stability and biocompatibility and prevents particle
aggregation [78].
3. Biological/Biochemical Effects
Metallic-based NPs are chosen with respect to biocompatibility, low cytotoxicity, or for
synergistic. The radiosensitization effects of metallic NPs can be categorized in three groups: the
physical effects, the chemical effects and the biological effects. The physical dose enhancement
leads to chemical effects (e.g., oxidative stress), which consequently lead to biological effects.
Biological effects refer to cellular damage and include DNA damage and/or DNA repair
inhibition, cell cycle effects, and cell death. Radiosensitization directly depends on the cellular
and subcellular distribution of the NPs, which may damage specific cellular components such
as the cell membrane, cytoplasm, nucleus, mitochondria, and endoplasmic reticulum (ER),
as well as other organelles [46,49,89]. Sometimes theoretical models differ from experimental
studies, which suggests that we still do not completely understand the biologically driven
processes [90]. This confirms also that the physical effect alone (e.g., radiation type, NP
concentration) is not responsible for the overall radiosensitizing effect. A summary of important
aspects of the biological/biochemical mechanisms of NPs radiosensitization is presented in the
paper by Rosa, Connolly et al. [63,91,92].
3.1. Nanotoxicity
The toxicity of the metallic NPs remains a great challenge to overcome in the cancer
nanotechnology and is perhaps one of the main reasons for the limited number of clinical
trials with NPs. Nanotoxicity depends on multiple factors such as the size, surface area,
shape, concentration, surface coating, and charge of the NPs. Size dependent cytotoxicity
was confirmed in vitro as well in vivo studies. Coradeghini et al. monitored the cellular
uptake and toxicity of 5 nm and 15 nm AuNPs in different concentrations and incubation
times using TEM and colony forming assay and found that only 5 nm NPs were toxic after
72 h at a concentration higher than 50 mM [41]. Yamagishi et al. studied the toxicity of
subnanosized Pt particles with diameter less than 1 nm administered to BALB/c mice.
Inflammation and hepatocyte death were observed for Pt doses higher than 15 mg/kg.
However, nephrotoxicity and disruption of kidney functions were not observed in mice
which were exposed to 8 nm PtNPs [93]. Pelka et al. also observed that there is an increase
in toxicity with the decrease in diameter between <20 nm, <100 nm, and >100 nm particles
in vitro human colon carcinoma cell line (HT29) [94]. Smaller size implies greater surface
area and area to volume ratio per given mass and this may increase the biological reactivity
and consequently the level of toxicity. Zhang et al. observed that low concentrations
(<75 µg/mL) of very inert spherical AuNPs with an average diameter of about 15 nm
do not affect the cell viability obviously and have no obvious cytotoxicity [95]. However,
concentrations of AuNPs, with the same average particle size, above 150 mg/mL are toxic
and lead to a decrease in cell viability. Conor et al. studied cells treated with 25 mM
of citrate-capped AuNP spheres with an average diameter of 18 nm with Transmission
Electron Microcopy (TEM). No difference in growth rates compared to untreated cells over
the course of 5 days was observed [96].
Nanotoxicity is closely associated with NPs biokinetics, cell uptake, NPs coating agent
and surface charge. Carboxyl coated Iron NPs AgNPs show greater toxicity compared
to amine coated [97]. Uncoated Ag NPs were found were to be more toxic than coated
ones [98]. In vivo studies demonstrated that PEG-coated 13 nm Au NPs injected to BALB/C
mice induce inflammation and apoptosis in the liver and spleen [99]. The positive surface
charge of NPs enhances the probability of cellular uptake in combination with the negative
charged plasma membrane [100].
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3.2. Cell Uptake and Localization
The radiosensitizing effect of metallic NPs depends strongly on the uptake by the
cells, as well as on their intracellular distribution. There are many factors that influence
the uptake of a NP, such as material, size, shape, surface charge, functionality some of
which are described below [101,102]. NPs can enter the cell interior through energy-
independent process such as simple diffusion, however most commonly NPs enter the
cell membrane through the energy-dependent process, endocytosis. Through endocytosis
the NPs from the extracellular environment enter the cell interior by vesicles that are
generated from the cell membrane [103]. The cellular uptake route is very important for
the NPs, since it determines the fate of the NPs, their lifespan and circulation inside the
cell and their ability to reach certain organelles for targeted purposes or for drug releases.
Endocytosis is mainly divided into two categories, phagocytosis and macropinocytosis.
Phagocytosis is responsible for the uptake of vesicles with size in the µm range. Pinocytosis
involves the uptake of fluids containing particles by vesicles of smaller size than those
generated during phagocytosis. Pinocytosis is subdivided into macropinocytosis and
micropinocytosis, with the latter being responsible for NP uptake. Micropinocytosis is
also referred to as receptor-mediated endocytosis (RME). In most cases, NPs including
metallic NPs are accumulated in the cytoplasm and are localized in vesicles such as
endosomes and/or lysosomes or in the endoplasmic reticulum (ER) and are rarely seen
inside the nucleus [104–107]. This sometimes creates conflict with those who associate NP
radiosensitization with DNA damage. Peckys et al. used liquid scanning TEM to monitor
30 nm gold NPs uptake, which after 24 h incubation accumulated in these vesicles and
formed clusters [108]. Ma et al. also used AuNPs and noticed that the internalized AuNPs
eventually accumulated in lysosomes and caused impairment of lysosome degradation
capacity through alkalinization of lysosomal pH. They also noticed that AuNPs increase
autophagosome accumulation [104].
3.3. Oxidative Stress
Radiation causes cellular damage through direct and indirect mechanisms. Oxida-
tive stress post IR refers to the excess production of reactive oxygen species (ROS) due
to radiolysis of water molecules. These are oxygen-containing radicals and nonradical
derivatives of oxygen. The main radical species are hydroxyl radical (•OH), singlet oxygen
(O2), hydroxyl peroxide (H2O2), and superoxide (O−2), with the first two being the most
reactive and damaging to the cells. In physiological environments, ROS are generated
from oxygen mainly in mitochondria and serve as cell signaling molecules for normal
biological processes. However, increased levels of ROS can cause severe cellular damage,
oxidative stress, DNA damage, and lipid peroxidation [109,110]. This is why ROS are an
important contributor to cellular damage of sparsely ionizing sources, such as X-rays and
electrons, [111]. It is therefore very important to understand the link between the properties
of metallic NPs and the intracellular generation of ROS when the NPs are exposed to IR.
Radiation-induced damages and increased levels of ROS generation within cells can alter
the antioxidant balance causing severe damage or cell death. NPs are located primarily
in the cytoplasm inside vesicles and not very often near the nucleus. Radiation-induced
ROS from irradiation of NPs do not extend far from the surrounding area, which makes it
necessary to understand the local biochemical effects caused by the created ROS. The Syn-
ergistic effects of metallic NPs with IR was found in tumor cells, mitochondria, and other
organelles which proves the idea of a complex cellular damage [112,113]. Mitochondrial
(MtDNA) DNA damage are one the things that can trigger cell death such as apoptosis.
Taggart et al. used AuNPs and identified radiosensitizing effects involving mitochondria.
In these studies, they used a low energy ultrasoft X-ray microbeam (278 eV carbon K-shell
X-rays) in combination with AuNPs and no nuclear DNA damage was detected, which
led them to the conclusion that the radiosensitization was mostly driven by mitochondrial
damage [114,115]. SUM159 triple-negative breast cancer (TNBC) cells in mice showed sen-
sitizing effects through oxidative stress when irradiating mice with X-rays in combination
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with AU-TiO2 dumbbell-like NPs (~70 nm) [116]. In addition, AuNPs induction of ROS
was seen to play again an important role in the radiosensitization of human U251 glioma
cells with AgNPs (15 nm). AgNPs were found also to induce high levels of oxidative stress
in TNBC (Triple-negative Breast Cancer) cells, which are more vulnerable to reagents that
evoke oxidative stress compared to that of the non TNBC cells [117]. Magnetic Fe-oxide
NPs (IONPs, 10 nm) functionalized with the antibody cetuximab, were found to sensitize
EGFRvIII-overexpressing glioblastoma (GBM) cancer cells, whereas ROS production was
involved [118]. Gd oxide 3 nm NPs in non-small cell carcinoma cell lines, irradiated with
carbon ions showed increased cell death, related to oxidative stress [52].
3.4. Effect on Cell Cycle
In eukaryotes cells that contain nucleus, the cell cycle consists of four phases G1, S, G2
and M. For most mammalian cells growing in culture the S phase is usually in the range of
6–8 h, the M phase less than an hour, G2 is in the range of 2–4 h and G1 is 1–8 h, making
the total cell cycle of the order of 10–24 h, depending on the cell type. Mother cells grow
and copy their DNA and then split into two daughter cells. G1 phase is the first gap, where
the cell grows and prepare for later phase. S phase is the synthesis phase where the DNA
makes a complete copy (DNA replication) and duplicates the centrosome, a microtubule
structure, which helps separate DNA during M phase. G2 phase is the second gap, the cell
grows further, makes proteins and organelles and prepare for later phase. Finally, M phase
is the Mitotic phase during which the cell divides its copied DNA and cytoplasm into
two daughter cells. In this phase DNA condenses into chromosomes which are separated
by a microtubules structure called mitotic spindle. Throughout the cycle, the cell has to
check for any present damage, and more importantly, DNA damage. To do this, there are
checkpoints between the previously described cell cycle phases. First, the G1 checkpoint
checks for any DNA damage and ensures environmental conditions. If all is well, the cell
progresses to the S phase, if not, it goes into cell cycle arrest (G0 phase). Second, the G2/M
checkpoint, which happens in the end of G2 phase, right before Mitosis, is monitoring cell
size and DNA replication. It checks whether the DNA is intact and properly replicated. If
not, it goes into cell cycle arrest to perform DNA repair. IR is in some cases found to be
responsible for cell cycle arrest by activating G1 and G2/M checkpoints, as it induces DNA
damage, which the cell has to repair afterwards [119,120]. According to the cell cycle phase
during IR, cells express different levels of radiosensitization. More specifically, cells in late
G2/M phase are the most radiosensitive, following G1, early S and late S [121]. Therefore,
the use of metallic NPs especially in G2/M cells can enhance the radiotherapeutic effects
on cancer cells.
Several NPs such as Au, Ag, Gd, TiO2, and Fe oxide, were shown to radiosensitize
cells by inducing cell cycle arrest. AuNPs with sizes ranging from 5 to 50 nm, used in
several cancer cell lines (e.g., HEPG2, DU-145, A375, MDA-MB-231), lead to increased cell
death, growth inhibition and in general in a DEF between 1.2 and 1.8, depending on size,
surface modification, cell line and type and dose of IR [122–125]. Cells were irradiated with
neutron (Average energy: 9.8 MeV, LET: 30–40 KeV/µm)/137Cs 5Gy/γ-irradiation and
5GyE/neutrons, 2Gy/137Cs, 4Gy/ 6-MV X-ray, respectively. In the case of HEPG2 cells,
the effects produced by neutrons were found to be more pronounced than with X-rays
when combining IR with GNPs. The combination of Glu-NPs (glucose-capped NPs) with
IR in DU-145 inhibited cell proliferation by 26.8%, in contrast to IR alone (7.4%). Again, in
MDA-MB-231 cells, compared to the inhibition with IR alone (7.07), the combination of IR
with Glu-NPs inhibited cell proliferation by 22.55% and 32.14% for 16 nm and 45 nm size,
respectively. On the other hand, functionalized Fe oxide NPs (10 nm) used in WEHI-164
(fibrosarcoma) cells and MTiO2 (mesoporous TiO2 NPs (45 nm)) used in 4T1-Luc (mouse
carcinoma) cells, irradiated with 60Co γ-teletherapy Irradiator and X-rays respectively,
showed cell proliferation inhibition [52,126,127]. More specifically, the irradiation of cells
with 2Gy with the presence of Fe oxide NPs, resulted in 34–57% proliferation in HT1080
cells and 60–88% in WEHI-164 cells in respect to IR alone (88% and 96% respectively for
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each cell line). Finally, in 4T1-Luc cells x-ray irradiation in the presence of MTiO2 peptide-
conjugated NPs effectively inhibited cell migration, as seen by cell migration and invasion
assay (clonogenic assay). Gadolinium oxide NPs used in A549, NH1299, and NH1650 cells
(all non-small cell carcinoma cells), irradiated with 2Gy carbon ions, resulted in a DEF of
1.1–1.2 [52]. Cell cycle arrest was observed more in the NH1650 cells.
Cell cycle inhibition is in addition to the NPs, dependent on the LET of the radiation.
Cells are most radiosensitive in the M and G2 phases, and most radioresistant in the late S
phase, as described above. Typical LET values at the tumor region for the different types
of IR are the following: 2 KeV/µm for 250 kVp X-rays, 0.3 KeV/µm for Cobalt-60 γ-rays,
0.3 KeV/µm for 3 MeV X-rays, 12 KeV/µm for 14 MeV neutrons and 100–200 KeV/µm
for heavy charged particles. Data show that at the same doses, high-LET irradiation is a
more potent inducer of cell cycle delays than low-LET irradiation [128]. In general, more
pronounced delays in S and G2 phase were observed with increasing LET. The role of cell
cycle regulatory proteins is such that TP53 is controversial between high- and low-LET.
Extensive delays in the G2 phase of cell populations were reported to occur comparing
high-LET (up to 300 KeV/µm) and X-rays [129,130]. A recent study agrees with these effects
and illustrate that breast cancer cells were arrested in the G2/M phase after irradiation with
X-rays or carbon ions, and a more obvious increase in the G2/M phase ratio was observed
in both cell lines after irradiation with carbon ions compared with X-rays at the same
dose [131]. In glioblastoma and normal human fibroblasts, an increasing G2 phase arrest
with LET (carbon ions 20–105 Kev/µm) was also confirmed [132]. Experiments on human
fibroblasts showed differences between wildtype and TP53 mutant cells after x-irradiation,
but these differences disappeared with increasing LET [128]. Exposing lymphoblastoid
cells to nitrogen (140 KeV/µm) and iron ions (1,000 KeV/µm) gave a pronounced G2 phase
delay and a greater inhibition of S phase compared to X-rays [133,134]. When compared
a-particles with γ-radiation G2 phase arrested cells were similar for both types of IR, but
G1 arrest was reduced in a-particles compared to γ-rays [135]. Exposure to protons ions
(7 to 28 keV/µm) revealed a G2 arrest and for low doses (1 Gy), a G1 arrest after both
proton and X-irradiation [136]. In contrast to high-LET irradiation, 3T3 fibroblast cells
irradiated with soft X-rays (dose rate: 550 µGy/hr), showed that the highest percentage of
irradiated cells were in G0/G1 phase compared to the control cells [137]. Results of this
study suggest that low-dose soft x-ray radiation might cause an initial pause, followed by
a significant increase, in proliferation. Another study which used X-rays with Hela cells
showed that proliferation ability of cells irradiated with X-rays decreased with increasing
doses. Within 24 h following irradiation, the S-phase of cells with different doses were
decreased gradually and within 30 h following irradiation, the S phase exhibited a gradual
increase. As for G1 phase, the higher the irradiation dose received, the greater the tendency
of G1 phase reduction. Correspondingly, increased dose of irradiation resulted in a greater
G2/M delay. Cells exposed to 4, 6, and 8 Gy returned to a normal cell cycle within 36 h,
and cells exposed to >10 Gy did not return to normal levels within 48 h after IR [138].
3.5. Effect on DNA Damage
DNA damage plays a key role in cancer treatment. Irradiation alone can lead to a
significant amount of DNA damage, such as SSBs and DSBs. However, the combination of
metallic NPs with IR increases the severity and complexity of DNA damages. As previously
mentioned, the physical stage includes both direct and indirect radiation actions and the
use of metallic NPs can increase the amount of indirect actions of IR through the produced
low energy secondary electrons, which leads to an increased ROS production. However,
since NPs are rarely seen inside the nucleus and are more often trapped in cytoplasmic
vesicles or in the ER, ROS do not extend far from the surrounding area and may not
reach the DNA inside the nucleus. That is why early DNA damage (up to 1 h post IR) is
attributed to NPs that have entered the nucleus or to these located near the perinuclear
region, whereas late DNA damage is related to indirect effects [139]. Studies with gel
electrophoresis on plasmids showed that metallic NPs can increase the number of initial
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DSBs [139,140]. Studies on AuNPs showed an increased radiosensitization due to DNA
Damage. MDA-MB-231 breast cancer cells were sensitized by 2 nm AuNPs through the
induction of DNA damage [141]. Immunofluorescence assays after exposure to X-rays in
combination with AuNPs, quantified γ-H2AX and 53BP1 foci and lead to the conclusion
that AuNPs have an impact on DNA repair [77,89]. Others do not report any influence
on DNA repair due to the use of AuNPs [77,142,143]. Another study on Gd-based NPs
suggest that NPs sensitize the cell by amplifying the radiation effects only in the cytoplasm
and not in the nucleus, since NPs are not located inside the nucleus [144]. Glioblastoma
cells were irradiated with micelles loaded with gold and superparamagnetic Fe oxide NPs
(SPIONS), which lead to an ∼2-fold increase in density of double-stranded DNA breaks
after γh2ax detection [145]. Many times, combined radiation treatment with different
sizes of AuNPs (50 nm, 5 nm, 18 nm) and specific drugs like doxorubicin and cisplatin
is very effective, leading to high levels of DNA damage and apoptosis in cancer cells
(e.g., glioblastoma, MCF-7) [146–148]. ZnO NPs (7 nm) reportedly sensitized SKLC-6 lung
cancer cells by inducing DNA damage; however, they did not sensitize MRC-5 normal lung
cells [149]. This also leads to the conclusion that depending on the histological area NP
radiosensitization vary. Another factor that also alters the sensitizing effect is the size and
shape of NPs. In HepG2 cells DNA damage and chromosomal breaks was correlated to
small NPs (5 nm), and not to larger ones (20 nm) [150]. Also, in HepG2 cells, Multiwalled
Carbon Nanotubes (MWCNTs) (10–30 µm/8–15 nm, 0.5–2 µm/8–15 nm) induced single-
strand DNA damage, where MWCNTs (10–30 µm/20–30 nm) did not [151]. Finally, AuNPs
(3.1 nm) with positive charge induce the highest amount of damage compared to that of
the negative ones [152].
3.6. Effect on Apoptosis, Autophagy and Senescence
Apoptosis is a type of programmed cell death, which is mediated by caspases, and
can be stimulated by internal or external factors such as pathological factors, oxidative
stress, death receptor proteins, chemotherapy, chemical exposure, and radiation. Apoptosis
is divided in two categories: extrinsic and intrinsic. Intrinsic apoptosis is triggered by
mechanisms related to the endoplasmic reticulum or mitochondria [153]. Autophagy
refers to a heterogeneous group of cells signaling pathways, which enables eukaryotic
cells to deliver cytosolic components to the autophagosomes-lysosomes for degradation
and to recycle nutrients. Autophagy is usually stimulated by hypoxia, chemotherapy,
or growth factor deprivation, and plays an important role in mediating cell death [154].
NP uptake happens primarily in the cytoplasm and as previously mentioned, NPs are
many times located inside lysosomes or autophagosomes. Many studies imply that NP
radiosensitization is accompanied with autophagosome accumulation, which may possibly
lead to autophagic cell death [104]. However, in the past, studies indicated that NPs
were not efficient to activate autophagy due to cellular defense mechanisms against NP-
induced stress. Until now, it is not clear how NP radiosensitization leads to cell death and
the detailed biological mechanisms are not well understood. Liang et al. reported that
AuNPs in a size-dependent manor could block autophagy through lysosomal impairment
leading to autophagosome accumulation [104]. Also, the use of AgNPs in glioma cells
inhibited autophagy leading to increased levels of ROS and apoptosis [155]. Several studies
show that AuNPs in combination with IR induce higher levels of apoptosis in cancer
cells [143,156]. The size of NPs plays also an important role in apoptosis. Apoptosis rate
on Lovo cells (human colon carcinoma) induced by AgNPs (10, 20, 40, 60 and 100 nm) was
found negatively correlated with particle size [157]. The same was observed in HepG2 cells
incubated with silica NPs (19, 43, 68 nm) [158]. U251 cells showed high levels of apoptosis
after radiosensitization with 15 nm Citrate AgNPs [159]. Finally, after radiation, surviving
cells may become resistance and regrow, but also some cells may undergo senescence, the
so-called therapy induced senescence. These cells will undergo cell cycle arrest and their
cell divisions are cessanated. The cell cycle arrest for normal somatic cells that undergo
senescence is irreversible. However, the cell cycle arrest for cells that undergo radiation
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induced senescence is reversible and these cells can reenter the cell cycle again [160], which
is essential for an efficient and successful radiotherapy. One of the main processes of action
for NPs is the ROS production and cellular senescence mediated after ROS production [161]
is of great importance and should be further studied.
4. Exp. Procedures to Study the Biological Effects of NPs’ Radiosensitization
Below, some methods to determine the radiosensitization effects of NPs after radiation
are described. A number of different experiments is needed to get a holistic approach and
to extract all the possible outcomes of radiosensitization based on DNA Damage, oxidative
stress, cell survival (e.g., apoptosis, autophagy), cellular senescence, and signaling.
1. Transmission electron microscopy (TEM): TEM can be used to monitor the cellular
uptake of NPs and it can be used to detect DNA damage after IR in the presence and
absence of NPs. Sample preparations for TEM analysis consists of several stages. After
IR, the basic steps for cell or tissue preparation are the following: fixation in aldehyde
buffer solution, embedding in gelatin, post fixation in osmium tetroxide, dehydration
in ethanol, and embedding in resin (epoxy or acrylic). The choice of fixative and
resin depends on the aim of the study (ultrastructural or Immunocyto-histochemical).
The chemicals used for these stages such as the aldehyde solution for fixation are
adequate to simultaneously preserve the ultrastructure morphology of cell organelles
and the antigenicity. However, all chemical preparation stages, if not applied correctly,
may lead to image artifacts. For a more detailed information, the reader can resort
to a recent technical note about all the technicalities regarding TEM [162]. There
exist several other techniques to study DNA damage, e.g., Immunocytochemistry
and Gel Electrophoresis, which are considerably more timesaving, require fewer
demanding skills and protocols, and are less expensive. However, for detection of
type and location of the DNA damage, TEM is unique since the details of the damage
cannot be detected in such magnification and resolution (nm scale) with any other
method. One disadvantage with TEM is the difficulty in quantifying the damage.
Usually, only 10–50 cells are analyzed each time, so the method provides better quality
than other methods but cannot accurately quantify the results. However, the use of
TEM was performed for the detection of both single and double staining to detect
clustered DNA damage and especially DSBs after IR [163,164]. TEM uses normally
the immunogold-labelling technique to characterize the DNA damage. Primary
antibodies target specific repair proteins are localized by secondary Au-conjugated
antibodies, similar to immunocytochemistry methodology. TEM was not used to
study DNA damage induced NP radiosensitization until now, but it was used to
monitor cellular uptake and distribution of NPs [77,105,165]. Moreover, recently, the
technical use of TEM was thoroughly described as a means of studying NP-induced
radiosensitization in vitro [162].
2. Flow cytometry (FC): Flow cytometry can be used for DNA damage detection and cell
cycle analysis. Propidium iodide is the most commonly used dye to quantitatively
assess DNA content, and it is a very useful technique to study different checkpoints
throughout the cell cycle [119]. Though flow cytometry is broadly used in radiation ex-
periments, cell cycle analysis related to DNA damage-induced NPs radiosensitization
was not performed until now. For instance, G2/M checkpoint prevents cells with dam-
aged DNA from entering Mitosis. Phosphorylation at Ser10 of histone H3 is tightly
correlated with chromosome condensation during mitosis [166]. An antibody that
specifically recognizes the phosphorylated form of histone H3 (p-histone H3 Ser10)
is used to identify mitotic cells. Cells are co-stained with anti-p-histone H3 Ser 10
antibody and propidium iodine to distinguish mitotic cells from G2 cells [167]. Milner
et al., used flow cytometry on CHO cells to access DNA damage after irradiation with
60Co γ-source [168]. Nucleotides were extracted from cells, then they were stained
with the fluorescent dye ethidium bromide and then exposed to laser light within
FC. Flow cytometry can be also used to monitor NP uptake. For example, Shapero
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et al. [169] used flow cytometry to investigate cellular uptake and final localization of
silica NPs of different sizes (50, 100, and 300 nm) inside A549 cells as a function of
time. They showed that the uptake rate of silica NPs decreases with size; however,
due to fluorescent intensity of NPs they suggested that results might be misleading if
are not normalized.
3. Immunofluorescence: Immunofluorescence uses primary antibodies, labelled with
fluorescent secondary antibodies for visualization, specific to targeted DNA repair
enzymes. The most common target for DNA damage detection, such as DSBs, is
the phosphorylated histone γ-H2AX (phosphorylation at serine 139). Foci represent
the DSBs in a 1:1 manner and are used as a DNA damage biomarker. Other DNA
repair markers include RAD51, 53BP1 (p53-binding protein 1), phospho-p53, and
PARP1 [170]. However, the specificity whether such DSB markers recognize only
DSBs is a controversial issue. γH2AX also appears in SSB sites [171]. Beside repair
enzymes, primary antibodies can be used to label the damage itself. In this case, the
antibodies bind to specific DNA lesions such as 8-oxo-dG, which is used to detect
base lesions [172]. Recently electrophoresis-based DNA fractionation methods were
used to quantify DNA damage. Detection and quantification of γ-H2AX and 53BP1 is
very often employed to assess metallic NP-induced radiosensitization [77,173].
4. Agarose Gel Electrophoresis (AGE): DNA lesions can be identified through gel elec-
trophoresis. This is a fast method that quantifies the average density of breaks and
a variety of DNA lesions in nanogram quantities. AGE can be divided into two
main groups: 1) Alkaline Gel Electrophoresis and 2) Glyoxal gel electrophoresis.
Agarose gels can separate a mixture of molecules such as DNA fragments between
50 bp (3% agarose) and 500.000 bp (0.1% agarose) in an agarose matrix, with suit-
able electrophoresis buffers [174]. The gels are stained with ethidium bromide and
the image acquisition of the DNA migration is performed with UV light. Alkaline
agarose gels are mostly used for single stranded DNA but it is also used for others
alkali-labile lesions as well such as 8-oxoguanine base lesions [175]. Glyoxal agarose
gel electrophoresis fractionizes DNA the same way, but it also keeps alkali-labile sites
intact.
5. Pulsed-field gel electrophoresis (PFGE) and Comet Assay (CA): Methods such as
the comet assay and pulsed-field gel electrophoresis (PFGE) [176,177] are based on
the detection of DNA fragments by electrophoresis. In comet assay, the cells are
embedded in agarose gel on a glass slide for microscopy and the DNA fragments
are fractionated by electrophoresis. Because of the tail-like images, this method is
called comet assay. In PFGE, cells are embedded in agarose gel, called plugs, and
then the cells are lysed in these agarose plugs. Only the DNA fragments such as DSBs
migrate in the gel, while the undamaged DNA remain. The CA does not need a large
number of cells for the analysis, and it is not expensive, but it cannot distinguish the
lengths of the DNA fragments. PFGE is there for better to be used for quantitative
purposes. Gel electrophoresis was already used in several studies concerning metallic
NP (especially AuNPs) radiosensitization [178,179].
6. Clonogenic Survival Assay (CSA): One gold standard technique to access cell death
and survival rate in radiobiology is CSA. After a stress induced situation, such as IR,
survival assay determines the ability of cells to proliferate and form colonies after a
few days’ incubation. Cells are seeded into petri dishes, treated with NPs, irradiated
and then replated in low seeding densities and left to grow colonies for a few days
(depending on the cell line). After these days, the colonies are stained with crystal
violet in 80–100% methanol [180]. The individual colonies are counted and then a
survival curve can be defined as a relationship between the radiation dose and the
fraction of cells that were able to replicate and form colonies. Clonogenic assay is
almost always used to compare cell radiosensitization in the presence and absence of
metallic NPs [26,179,181].
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7. TUNEL Assay: TUNEL (terminal deoxynucleotidyl transferase dUTP nick end label-
ing) staining, also called the TUNEL Assay, detects the DNA breaks formed when
DNA fragmentation occurs in the last phase of apoptosis [182]. TdT can label blunt
ends of double-stranded DNA breaks as it attaches to deoxynucleotides to the 3′-
hydroxyl terminus of DNA breaks. The nucleotides attached by TdT are stained with
a fluorescent dye. Tunnel assay is an alternative assay to agarose gel electrophoreses
to analyze the formation of DNA fragments during apoptosis. Teraoka et al., used
this assay to access apoptotic cells by counting TUNEL-positive cells [156].
8. Immunoblotting/Western blotting: Immunoblotting, or western blotting, is used to
identify changes in protein expression following treatment. In this assay, protein
expression is sampled at different time-points following X-ray irradiation to determine
how pretreatment with NPs enhances the radiation sensitivity. This is performed both
in the presence and absence of NPs [123]. This assay uses protein expression levels in
different time points after radiation. Primary antibodies can be selected according to
selected interest such as apoptosis, DNA damage and repair and oxidative stress.
9. Immunocyto/histochemistry for Cellular Senescence detection: There is a number
of senescence biomarkers. The most common markers are SA-β-Gal, senescence-
associated secretory phenotype (SASP) [183], cell cycle inhibitors p16Ink4a and
p21Cip1 [184], and lipofuscin [185]. Oxidative stress is one of the possible reasons lead-
ing to senescence. Irradiation alone can lead to increased senescent phenotype [186].
Since ROS production can be responsible for NP-induced radiosensitization, it is
essential to also study whether or not irradiated cells incubated with NPs lead to
increased senescence compared to the irradiated alone. Until now there are only few
groups who address senescence [173,187].
5. Clinicals Trials
5.1. The Use of NPs in Radiotherapy
Despite all the above challenges and the multiscale approaches for an effective NP-
boosted radiation therapy (RT), some clinical trials were already conducted with NPs.
Among the various types of the metallic NPs, Gadolinium based NPs are demonstrated
as a very promising agents for RT treatment. AGuIX Gadolinium-based NPs were passed
to phase II as radiosensitizers with Stereotactic Magnetic Resonance-guided Adaptive
Radiation Therapy (SBRT) for the treatment of lung and pancreatic cancer ((NCT number):
NCT04789486). Radiation by proton therapy associated to AGulX NPs injection is also on
phase II for patients with tumor of the cephalo-spino-iliosacral axis, particularly base of
the skull, pharyngeal wall, parapharyngeal and retropharyngeal lymph nodes etc. ((NCT
number): NCT04784221). Hafnium oxide (hafnia, HfO2) are also shown to be a promising
sensitizer for radiation therapy as well as x-ray contrast agents [188,189]. Nanobiotix (
http://www.nanobiotix.com/_en/ (accessed on 28 April 2021)) developed NBTXR3, which
are functionalized HfO2 NPs. These NPs are 50 nm sized crystalline nanoparticles, with a
bearing negative surface charge. Their design was for direct local intratumoral injection
and subsequent radiosensitization [67,190]. Until recently, several clinical trials were
carried out using NBTXR3 crystalline nanoparticles-RT combination. A phase I trial with
the use of NBTXR3 in sarcoma patients started in 2011 and completed in 2015 ((NCT
number): NCT01433068) [191]. More phase I/II trials and one phase II/III trial followed
which included participants with various cancer types such as head and neck cancer
(squamous cell carcinoma) ((NCT number): NCT01946867), rectal cancer, hepatocellular
carcinoma (liver cancer) ((NCT number): NCT02721056), prostate cancer ((NCT number):
NCT02805894), and adult soft tissue sarcoma ((NCT number): NCT02379845). All the
previously mentioned clinical trials are summarized below in Table 1.
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Table 1. Combined nanoparticle-radiation therapies in cancer patients. Table includes currently undergoing or completed clinical trials (not yet recruiting, recruiting, active, completed).
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5.2. Limitations and Challenges in Using Nanoparticles in Clinic
To introduce nanoparticles into clinical use, we have to take into consideration several
biological and technical limitations. Even though each individual type of NP will provide
different challenges, most of nanomedicines will face the same limitations. Here, we will
summarize very briefly these limitations. Biological challenges include nanotoxicity, as
well as biodistribution or controlling passage of NPs across biological barriers and into
specific targeted cells or tissues. These are directly connected to surface functionalization
and particle size. Specific surfactants, coating (e.g., PEG), or the use of lipids, peptides, and
proteins (e.g., human serum albumin) can enhance biocompatibility and are acceptable
for clinical use [192,193]. Some of these types of functionalized nanoparticles may also
provide additional advantages for internalization and crossing of biological barriers [194].
Another major issue is the crossing from preclinical (in vivo experiments) to clinical use.
Due to the heterogeneity of humans and animal species the optimizations in animal models
(e.g., small animals), may not work the same in humans. Added to this, is the fact that
unlike animals, the biodistribution (in organ and tissue level) of nanoparticles in humans
cannot be easily determined. The only way to monitor nanoparticle fate and biodistribution
(e.g., penetration through tumor) in humans is through biopsies [195] or imaging-based
nanoparticles [196,197]. However, the need to determine the biodistribution of NPs can be
reduced significantly, by using tumor targeted functionalized NPs in lower concentrations.
In that case, the toxicity and the effectiveness of treatment could be also monitored by other
means than biopsies, enabling this way the incorporation of NPs into cancer treatment.
6. Discussion
To summarize all of the above results and for better understanding of the key differ-
ences between RT and combined RT with NPs, we provide below Figure 3.
Figure 3. A summary of key point differences between RT and combined NP radiotherapy.
Apart from the material of the NPs and the use of a specific radiation source, the
choice of the delivery route and the interactions of NPs with the biological systems (for
both tumor and normal cells), which depends on the physical and chemical characteristics
of NPs [3], contribute significantly to the level of radiosensitization. However, since we
discuss about the clinical application of NPs, it would be important here to address also
the matter of NP elimination from the body after their use.
The use of nanomaterials in clinical research radiotherapy is troubleshooting. The fate
of nanoparticles after the delivery inside the human body raise concerns about their chronic
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accumulation and consequently about the patient safety. This is one of the main reasons
why the application of NPs as radiosensitizers is very limited and very rare in clinical
trials. The United States Food and Drug Administration (FDA) requires nanoparticles that
can be metabolized and excreted from the body once they have fulfilled their purpose.
Studies show that nanoparticles injected into the bloodstream of laboratory animals are
found in organs including the liver, spleen, heart, and brain. Nanoparticles in the blood
can be filtered out by the kidneys and excreted in urine. Those administered intravenously
circulate in the blood until they are cleared from circulation and eliminated from the body
by two main mechanisms: renal elimination and hepatobiliary elimination [198]. Most
nanoparticles with dimensions less ∼5.5 nm undergo renal elimination by the kidneys
and leave the body via the urine [199]. Based on this knowledge, many strategies for
tuning nanoparticle renal elimination were since developed using nanoparticle size, core
density, surface charge, and surface chemistry. Even if larger sizes of NPs ranging from
20 to 60 nm provide better cellular uptake, smaller NPs still accumulate in tumors due
to the EPR effect and because of the smaller size diffuse further into the tumor tissue
and afterwards they can be eliminated from the blood stream [200,201]. Biodegradable
NPs that are larger than 5 nm can be disassembled, broken down, or metabolized and
may return to the systemic circulation [202,203]. On the other hand, most of the larger
nonbiodegradable NPs become retained long-term in Kupffer cells [204], otherwise they
could undergo hepatobiliary elimination. Even then, however, they must undergo certain
barriers to enter the bile ducts and be removed. Eventually, the nanoparticles enter the
intestines and are removed from the body via feces. Sadauskas et al., reported that liver
clearance was about 9% in 6 months [205], and eventually this whole-body retention will be
a problem for FDA approval. In previous sections we discussed local intratumoral injection.
This is considered to be invasive depending on the tumor site, and there is relatively rapid
clearance of the drug-conjugated NPs from the tumor volume into systemic circulation,
which could lead to drug toxicity in surrounding tissues [206].
Among the metallic nanoparticles, gold is a very promising candidate and even though
it is expensive, it could be used selectively for cancer radiotherapy in small amounts. A
problem though with gold, is that is causes skin discoloration [207]. Nanoparticles <6
nm in a biodegradable matrix were developed for better clearance to extend blood life
and reach the kidneys. However, during the long circulation they might be taken up by
macrophages and get trapped in lysosomes [208]. High-Z NP x-ray dose enhancement is
better with kV photons than megavoltage, but MV instruments are the ones currently used
clinically due to better penetration to deep located tumors. In addition, experiments show
good dose enhancement with less than ~2% Au by weight, even with MV photons [209].
Even if MV photons are more abundant in cancer therapy, kV photons come again into
play with microbeams or minibeams [210]. kV machines are less expensive, require less
shielding, and could make NP-induced cancer radiotherapy available to most countries.
Moreover, based on all the above things which are discussed in this paper, current radiation
therapy modalities starting from low-LET (X-rays and electrons) up to protons and carbons
(high-LET) offer unique tools for clinicians to achieve the ultimate goal, i.e., tumor control
and minimization of normal tissue toxicity. Of course, each type of radiation type and
treatment carries its own constraints and limitations. The use of protons and carbons as
the main type of high-LET particles used in RT, come with the advantage of higher dose
delivery to the tumor area and minimum impact to the surrounding tissues compared to
low-LET RT treatments [211,212]. Nowadays, new very high-dose rate approaches evolved,
delivering exciting opportunities for cancer treatment called FLASH-RT. Based on cellular
and higher mammals’ studies, the suggested dose rates of up to 100 Gy/s, using protons
or X-ray/electrons synchrotron beams, will minimize the radiation toxicity. However,
FLASH-RT was not yet tested on human patients [213,214].
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7. Conclusions
The radiosensitizing and synergistic effects of metallic NPs are a combination of
physical and chemical dose enhancements properties, followed by a biological phase.
The magnitude of the dose enhancement depends on many physical, chemical, and bi-
ological parameters, e.g., the quantity and quality of the dose of the IR, the size, shape,
structure, coating, functionalization, concentration, of the metallic-based NPs, as well as
the availability of oxygen, the cell uptake, and the intracellular distribution. This review
also tries to present the complexity of the damage (e.g., DNA damage, oxidative stress)
either from direct or indirect effect. The emission of electron and the consecutive ROS
clusters favor this induction of complex damage. There is still need for optimized protocols
in radiotherapy treatment for a translation to the clinical practice. The entrance of the
metallic-based NPs in clinical practice to improve the effect of IR therapy demands the con-
sideration of different effects/mechanisms. This includes the physical and chemical dose
enhancement effects, as well as the biological effects, including cellular uptake, localization,
toxicity, oxidative stress, effects on the cell cycle, DNA damage, apoptosis, autophagy, and
senescence. NPs or NP-based structures clinically used as radiosensitizers should ideally
be designed to have sensitivity to the tumor environment and specific stimuli, such as
temperature, pH, magnetic field, radiation, etc. Therefore, delivery techniques/routes of
NPs for RT applications also play a very important role in tumor sensitization, resulting
in radiotherapeutic dose enhancement. Thus, integrated strategies need to be developed
for an effective metallic nanoparticles radiosensitization. In this paper, we summarized all
the recent clinical trials based on metallic NP radiotherapy along with their limitations in
terms of clinical use. For the addition of NPs in preclinical, but most importantly, in clinical
research, it is now becoming clearer that in the future the construction of NPs should
be focused on targeting tumor sites specifically. Conventional radiotherapy alone was
tremendously improved. If we could manage to use all the knowledge about the material,
size, shape and functionalization, we would be able, at least in certain cancer types, to
introduce NPs or drug/NP-based structure in clinical trials and reduce the cytotoxic effects
on the surrounding tissues.
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